oxybutynin has been researched along with Neuralgia, Postherpetic in 24 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Neuralgia, Postherpetic: Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy, systemic exposure, safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM) in patients with postherpetic neuralgia (PHN)." | 9.24 | Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial. ( Brooker, C; Gavin, PD; Smith, A; Tremper, L; Williams, G, 2017) |
| "Qutenza is a high-dose capsaicin patch used to relieve neuropathic pain from postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN)." | 9.20 | Predictors of Response in Patients With Postherpetic Neuralgia and HIV-Associated Neuropathy Treated With the 8% Capsaicin Patch (Qutenza). ( Katz, NP; Mou, J; Paillard, FC; Stoker, M; Trudeau, J; Turnbull, B, 2015) |
| "To confirm the efficacy, tolerability, and safety of NGX-4010, an 8% capsaicin dermal patch (capsaicin 640 µg/cm(2) ), in patients with postherpetic neuralgia (PHN)." | 9.15 | A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. ( Backonja, MM; Blonsky, ER; Dunteman, E; Irving, GA; Lu, SP; Tobias, J; Vanhove, GF, 2011) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 9.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 8.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 8.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 7.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch." | 7.76 | Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. ( Amy Puenpatom, R; Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Summers, KH; Wei, R, 2010) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 6.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Despite currently available treatments, postherpetic neuralgia continues to be a challenging pain condition to treat." | 6.47 | Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. ( Pappagallo, M; Wallace, M, 2011) |
| "To evaluate the efficacy, systemic exposure, safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM) in patients with postherpetic neuralgia (PHN)." | 5.24 | Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial. ( Brooker, C; Gavin, PD; Smith, A; Tremper, L; Williams, G, 2017) |
| "Qutenza is a high-dose capsaicin patch used to relieve neuropathic pain from postherpetic neuralgia (PHN) and HIV-associated neuropathy (HIV-AN)." | 5.20 | Predictors of Response in Patients With Postherpetic Neuralgia and HIV-Associated Neuropathy Treated With the 8% Capsaicin Patch (Qutenza). ( Katz, NP; Mou, J; Paillard, FC; Stoker, M; Trudeau, J; Turnbull, B, 2015) |
| "To confirm the efficacy, tolerability, and safety of NGX-4010, an 8% capsaicin dermal patch (capsaicin 640 µg/cm(2) ), in patients with postherpetic neuralgia (PHN)." | 5.15 | A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. ( Backonja, MM; Blonsky, ER; Dunteman, E; Irving, GA; Lu, SP; Tobias, J; Vanhove, GF, 2011) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 5.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| " A high-concentration capsaicin 179-mg cutaneous patch (Qutenza™) is licensed in adults for chronic neuropathic pain in the EU, and neuropathic pain with post-herpetic neuralgia and neuropathic pain with diabetic peripheral neuropathy in the USA." | 5.12 | Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy. ( Casale, R, 2021) |
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 4.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| "The purpose of this study was to compare the cost effectiveness of a new 8% capsaicin patch, compared to the current treatments for postherpetic neuralgia (PHN), including tricyclic antidepressants (TCAs), topical lidocaine patches, duloxetine, gabapentin, and pregabalin." | 4.87 | Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia. ( Armstrong, EP; Malone, DC; McCarberg, B; Panarites, CJ; Pham, SV, 2011) |
| "Overall, 68 patients with PNP conditions, including facial neuropathy (severe trigeminal neuralgia in V2), polyneuropathy, post-herpetic neuralgia, and mononeuropathies, received 96 treatments with the capsaicin 8% patch." | 3.79 | The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. ( Poole, C; Roth-Daniek, A; Wagner, T, 2013) |
| "Qutenza is a high-potency capsaicin (8%) topical patch, labeled for treating pain associated with postherpetic neuralgia (PHN)." | 3.77 | Capsaicin 8% topical patch (Qutenza)--a review of the evidence. ( Jones, VM; Moore, KA; Peterson, DM, 2011) |
| "To compare healthcare resource utilization and costs of postherpetic neuralgia (PHN) patients initiating lidocaine patch 5% (lidocaine patch) or oral gabapentin/pregabalin." | 3.76 | Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. ( Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Puenpatom, RA; Summers, KH; Wei, R, 2010) |
| "To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch." | 3.76 | Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. ( Amy Puenpatom, R; Ben-Joseph, RH; Birnbaum, HG; Ivanova, JI; Kantor, E; Kirson, NY; Summers, KH; Wei, R, 2010) |
| "Treatment of chronic pain conditions is commonly assessed at specific endpoints at preset times during or after treatment by analysis of the total study population." | 2.78 | A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. ( Dahan, A; Krebs-Brown, A; Martini, CH; Olofsen, E; Passier, P; Stoker, M; Yassen, A, 2013) |
| "Despite currently available treatments, postherpetic neuralgia continues to be a challenging pain condition to treat." | 2.47 | Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. ( Pappagallo, M; Wallace, M, 2011) |
| "Several guidelines for neuropathic pain management and various effective drugs are available; however, neuropathic pain remains undertreated." | 1.48 | Efficacy Analysis of Capsaicin 8% Patch in Neuropathic Peripheral Pain Treatment. ( Fernandes, HL; Gama, R; Loureiro, MC; Pereira, FC; Tenreiro Pinto, J, 2018) |
| "Localized neuropathic pain (LNP) is a subgroup of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain, associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of NP." | 1.48 | Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. ( Chinellato, E; Del Balzo, G; Martini, A; Parolini, M; Picelli, A; Polati, E; Schweiger, V; Tamburin, S; Zanzotti, M, 2018) |
| "Additionally, gabapentin was given for neuropathic pain uncontrolled by opioids." | 1.37 | [Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer]. ( Ando, A; Nishimura, D; Shibahara, H; Suzuki, S; Uematsu, N, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 22 (91.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Casale, R | 1 |
| Shaparin, N | 1 |
| Nair, S | 1 |
| Vydyanathan, A | 1 |
| Hascalovici, JR | 1 |
| Gavin, PD | 1 |
| Tremper, L | 1 |
| Smith, A | 1 |
| Williams, G | 1 |
| Brooker, C | 1 |
| Tenreiro Pinto, J | 1 |
| Pereira, FC | 1 |
| Loureiro, MC | 1 |
| Gama, R | 1 |
| Fernandes, HL | 1 |
| Martini, A | 1 |
| Del Balzo, G | 1 |
| Schweiger, V | 1 |
| Zanzotti, M | 1 |
| Picelli, A | 1 |
| Parolini, M | 1 |
| Chinellato, E | 1 |
| Tamburin, S | 1 |
| Polati, E | 1 |
| Blair, HA | 1 |
| Martini, CH | 1 |
| Yassen, A | 1 |
| Krebs-Brown, A | 1 |
| Passier, P | 1 |
| Stoker, M | 3 |
| Olofsen, E | 1 |
| Dahan, A | 1 |
| Wagner, T | 1 |
| Poole, C | 1 |
| Roth-Daniek, A | 1 |
| Mou, J | 2 |
| Paillard, F | 1 |
| Turnbull, B | 2 |
| Trudeau, J | 2 |
| Katz, NP | 2 |
| Paillard, FC | 1 |
| Burness, CB | 1 |
| McCormack, PL | 1 |
| Riopelle, J | 1 |
| Kaye, AD | 1 |
| Andersen, HH | 1 |
| Sand, C | 1 |
| Elberling, J | 1 |
| Kirson, NY | 2 |
| Ivanova, JI | 2 |
| Birnbaum, HG | 2 |
| Wei, R | 2 |
| Kantor, E | 2 |
| Puenpatom, RA | 1 |
| Ben-Joseph, RH | 2 |
| Summers, KH | 2 |
| Amy Puenpatom, R | 1 |
| Webster, LR | 2 |
| Tark, M | 1 |
| Rauck, R | 1 |
| Tobias, JK | 2 |
| Vanhove, GF | 3 |
| Irving, GA | 1 |
| Backonja, MM | 1 |
| Dunteman, E | 1 |
| Blonsky, ER | 1 |
| Lu, SP | 1 |
| Tobias, J | 1 |
| Wallace, M | 1 |
| Pappagallo, M | 1 |
| Armstrong, EP | 1 |
| Malone, DC | 1 |
| McCarberg, B | 1 |
| Panarites, CJ | 1 |
| Pham, SV | 1 |
| Jones, VM | 1 |
| Moore, KA | 1 |
| Peterson, DM | 1 |
| Peppin, JF | 1 |
| Murphy, FT | 1 |
| Lu, B | 1 |
| Argoff, CE | 1 |
| Shibahara, H | 1 |
| Ando, A | 1 |
| Suzuki, S | 1 |
| Uematsu, N | 1 |
| Nishimura, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Feasibility of High-Dose Topical Capsaicin for the Treatment of Neuropathic Pain in Pediatric Sickle Cell Disease[NCT03899246] | Phase 1 | 10 participants (Actual) | Interventional | 2019-07-03 | Completed | ||
| A Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia[NCT00068081] | Phase 3 | 150 participants | Interventional | Completed | |||
| A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia[NCT00300222] | Phase 3 | 400 participants | Interventional | 2006-03-31 | Completed | ||
| A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain[NCT00082316] | Phase 2 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for oxybutynin and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Capsaicin 179-mg cutaneous patch in the treatment of post-surgical neuropathic pain: a scoping review of current evidence and place in therapy.
Topics: Adult; Capsaicin; Diabetic Neuropathies; Humans; Neuralgia; Neuralgia, Postherpetic; Pain, Postopera | 2021 |
Capsaicin 8% Dermal Patch: A Review in Peripheral Neuropathic Pain.
Topics: Administration, Cutaneous; Analgesics; Capsaicin; HIV Infections; Humans; Neuralgia; Neuralgia, Post | 2018 |
ZTlido--a new lidocaine patch for postherpetic neuralgia.
Topics: Anesthetics, Local; Animals; Humans; Lidocaine; Neuralgia, Postherpetic; Transdermal Patch | 2019 |
Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients.
Topics: Adult; Aged; Aged, 80 and over; Capsaicin; Databases, Factual; Dose-Response Relationship, Drug; Dou | 2014 |
Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.
Topics: Capsaicin; Diabetic Neuropathies; Humans; Neuralgia, Postherpetic; Pain Management; Peripheral Nervo | 2016 |
Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia.
Topics: Administration, Cutaneous; Capsaicin; Clinical Trials as Topic; Europe; Humans; Neuralgia, Postherpe | 2011 |
Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Topics: Administration, Topical; Amines; Anesthetics, Local; Antidepressive Agents, Tricyclic; Capsaicin; Cl | 2011 |
Review of current guidelines on the care of postherpetic neuralgia.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Capsaicin; Cyclohexanecarb | 2011 |
6 trials available for oxybutynin and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial.
Topics: Adult; alpha-Tocopherol; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Drug Combinati | 2017 |
A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia.
Topics: Aged; Aged, 80 and over; Capsaicin; Chronic Pain; Double-Blind Method; Female; Humans; Lidocaine; Ma | 2013 |
Predictors of Response in Patients With Postherpetic Neuralgia and HIV-Associated Neuropathy Treated With the 8% Capsaicin Patch (Qutenza).
Topics: Adult; Aged; Aged, 80 and over; AIDS-Associated Nephropathy; Analysis of Variance; Capsaicin; Dose-R | 2015 |
Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia.
Topics: Aged; Capsaicin; Double-Blind Method; Female; Humans; Male; Neuralgia, Postherpetic; Pain Measuremen | 2010 |
A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
Topics: Administration, Topical; Aged; Analgesics; Capsaicin; Dose-Response Relationship, Drug; Double-Blind | 2011 |
Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Topics: Aged; Anesthetics, Local; Capsaicin; Diabetic Neuropathies; Drug-Related Side Effects and Adverse Re | 2011 |
10 other studies available for oxybutynin and Neuralgia, Postherpetic
| Article | Year |
|---|---|
Expanding frontiers in telehealth: Video assisted at-home application of capsaicin 8% patch.
Topics: Capsaicin; Female; Humans; Neuralgia, Postherpetic; Pain Measurement; Sensory System Agents; Telemed | 2021 |
Efficacy Analysis of Capsaicin 8% Patch in Neuropathic Peripheral Pain Treatment.
Topics: Administration, Cutaneous; Aged; Capsaicin; Female; Humans; Male; Middle Aged; Neuralgia; Neuralgia, | 2018 |
Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy.
Topics: Aged; Analgesics; Anesthetics, Local; Drug Evaluation; Drug Resistance; Drug Therapy, Combination; E | 2018 |
The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis.
Topics: Capsaicin; Failed Back Surgery Syndrome; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neura | 2013 |
Transition from Injectable to Percutaneous Local Anesthetic Therapy in a Patient with Post-Herpetic Neuralgia.
Topics: Aged; Anesthesia, Local; Anesthetics, Local; Female; Humans; Injections, Subcutaneous; Neuralgia, Po | 2016 |
[Effective pain relief of post-herpetic neuralgia with capsaicin patch].
Topics: Capsaicin; Humans; Male; Middle Aged; Neuralgia, Postherpetic; Pain Measurement; Sensory System Agen | 2016 |
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Topics: Amines; Analgesics; Costs and Cost Analysis; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma- | 2010 |
Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.
Topics: Aged; Analysis of Variance; Anesthetics, Local; Comorbidity; Female; Health Care Costs; Humans; Insu | 2010 |
Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
Topics: Administration, Cutaneous; Capsaicin; Clinical Trials as Topic; Humans; Neuralgia, Postherpetic; Pai | 2011 |
[Oxycodone and pregabalin using transdermal fentanyl patch provided relief of symptoms for postherpetic neuropathic pain in a patient with non-small cell lung cancer].
Topics: Aged; Analgesics, Opioid; Carcinoma, Non-Small-Cell Lung; Fentanyl; gamma-Aminobutyric Acid; Humans; | 2011 |